News and Announcements
Immuron & Monash University to Develop a Clostridium Difficile Therapeutic
- Published January 31, 2012 4:06PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Melbourne, Australia, 31 January 2012: Australian biopharmaceutical company Immuron Limited (ASX:IMC), manufacturer of Travelan, has entered into a collaboration Agreement with Monash University to develop a product or products that will be aimed at both Prevention and treatment of Clostridium difficile (C difficile) infections.
The therapeutic will be based on Immuron’s hyper-immune colostrums platform technology, with its proven safety.
—–
To view the full article, please click the link below.
Company Updates
The Index Approach in Early-Stage Venture Capital: Reconsidered
The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]
The Future Is Now: The Evolution of Dealflow with Wholesale Investor
If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]
Investability of a Startup: A Comprehensive Guide for Angels and High-Net Worth Investors
Venturing into the Startup Scene Let’s dive into the intriguing world of startups. It’s a thrilling ride, isn’t it? Like finding a pearl in an ocean, spotting a promising startup amidst a sea of businesses is no easy task. This guide aims to light the way, focusing on the “The Investability of a Startup: 7 […]
Backed By Leading Investment Groups and Family Offices
